

Edgar Filing: IMMUNOGEN INC - Form 8-K

IMMUNOGEN INC
Form 8-K
January 24, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): JANUARY 24, 2003

IMMUNOGEN, INC.

(Exact name of registrant as specified in its charter)

MASSACHUSETTS	0-17999	04-2726691
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

128 SIDNEY STREET, CAMBRIDGE, MA 02139

(Address of principal executive offices) (Zip Code)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 995-2500

ITEM 5. OTHER EVENTS

On January 24, 2003, ImmunoGen, Inc. announced that the Company has regained the development and commercialization rights for cantuzumab mertansine (huC242-DM1) from GlaxoSmithKline plc. The press release announcing this event is incorporated herein by reference and filed as Exhibit 99.1 hereto.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits

EXHIBIT NO. -----	EXHIBIT -----
99.1	The Registrant's Press Release dated January 24, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOGEN, INC.

(Registrant)

Date: JANUARY 24, 2003

/s/ GREGG D. BELOFF

Gregg D. Beloff
Chief Financial Officer and
Vice President, Finance

EXHIBIT INDEX

EXHIBIT NO.

EXHIBIT

99.1

The Registrant's Press Release dated
January 24, 2003.